-
-
Overview
-
Specificity: Detects human VEGF. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Aflibercept.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Bulk Human IgG1 Isotype Control (IB1) [ICH2254]
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL methodPlease contact us at for specific academic pricing.
Background
Aflibercept biosimilar is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept biosimilar is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept biosimilar is produced in recombinant Chinese hamster ovary (CHO) cells.
-
- Properties
-
Overview